Sleep neurobiology from a clinical perspective

Sleep

Volumn 34, Issue 7, 2011, Pages 845-858

  España, Rodrigo A ^a   Scammell, Thomas E ^b  

^a WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Arousal; Dorsal raphe nucleus; Locus coeruleus; Thalamus; Tuberomammillary nucleus; Ventrolateral preoptic area; Waking

Indexed keywords

4 AMINOBUTYRIC ACID; ACETYLCHOLINE; AMITRIPTYLINE; AMPHETAMINE; ARMODAFINIL; CHLORPROMAZINE; CITALOPRAM; CLONAZEPAM; DEXAMPHETAMINE; DIAZEPAM; DIPHENHYDRAMINE; DOPAMINE; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; HISTAMINE; LORAZEPAM; METHYLPHENIDATE; MODAFINIL; MONOAMINE DERIVATIVE; NEUROTRANSMITTER; NORADRENALIN; NORTRIPTYLINE; OREXIN; SEROTONIN; TRIAZOLAM; TRIPROLIDINE; ZOLPIDEM; ZOPICLONE;

BRAIN NERVE CELL; DRUG MECHANISM; HUMAN; MESENCEPHALON; NEUROBIOLOGY; NONHUMAN; NONREM SLEEP; PONS; POSTERIOR HYPOTHALAMUS; PRIORITY JOURNAL; REM SLEEP; REVIEW; SLEEP; WAKEFULNESS;

HUMANS; HYPOTHALAMUS; NEURONS; PONS; SLEEP;

EID: 79959965737     PISSN: 01618105     EISSN: 15509109     Source Type: Journal    
DOI: 10.5665/SLEEP.1112     Document Type: Review

References (244)

1. España RA, Scammell TE. Sleep neurobiology for the clinician. Sleep 2004;27:811-20. (Pubitemid 38823381)
2. von Economo C. Sleep as a problem of localization. J Nerv Ment Dis 1930;71:249-59.
3. Moruzzi G, Magoun HW. Brain stem reticular formation and activation of the EEG. Electroencephalogr Clin Neurophysiol 1949;1:455-73.
4. Aserinsky E, Kleitman N. A motility cycle in sleeping infants as manifested by ocular and gross bodily activity. J Appl Physiol 1955;8:11-8.
5. Dement W, Kleitman N. Cyclic variations in EEG during sleep and their relation to eye movements, body motility, and dreaming. Electroencephalogr Clin Neurophysiol 1957;9:673-90.
6. Jouvet M, Michel F. New research on the structures responsible for the "paradoxical phase" of sleep. J Physiol (Paris) 1960;52:130-1.
7. Lindsley DB, Bowden JW, Magoun HW. Effect upon the EEG of acute injury to the brain stem activating system. Electroencephalogr Clin Neurophysiol 1949;1:475-86.
8. Posner J, Saper CB, Schiff N, Plum F. Plum and Posner's diagnosis of stupor and coma. 4th ed. Oxford University Press, 2007.
9. el Mansari M, Sakai K, Jouvet M. Unitary characteristics of presumptive cholinergic tegmental neurons during the sleep-waking cycle in freely moving cats. Exp Brain Res 1989;76:519-29.
10. Steriade M, Datta S, Pare D, Oakson G, Curro Dossi RC. Neuronal activities in brain-stem cholinergic nuclei related to tonic activation processes in thalamocortical systems. J Neurosci 1990;10:2541-59.
11. Lee MG, Manns ID, Alonso A, Jones BE. Sleep-wake related discharge properties of basal forebrain neurons recorded with micropipettes in head-fixed rats. J Neurophysiol 2004;92:1182-98. (Pubitemid 38931977)
12. Boucetta S, Jones BE. Activity profiles of cholinergic and intermingled GABAergic and putative glutamatergic neurons in the pontomesencephalic tegmentum of urethane-anesthetized rats. J Neurosci 2009;29:4664-74.
13. Gritti I, Mainville L, Mancia M, Jones BE. GABAergic and other non-cholinergic basal forebrain neurons, together with cholinergic neurons, project to the mesocortex and isocortex in the rat. J Comp Neurol 1997;383:163-77. (Pubitemid 27250789)
14. Henny P, Jones BE. Projections from basal forebrain to prefrontal cortex comprise cholinergic, GABAergic and glutamatergic inputs to pyramidal cells or interneurons. Eur J Neurosci 2008;27:654-70. (Pubitemid 351239287)
15. Satoh K, Fibiger HC. Cholinergic neurons of the laterodorsal tegmental nucleus: efferent and afferent connections. J Comp Neurol 1986;253:277-302. (Pubitemid 17181056)
16. Hallanger AE, Levey AI, Lee HJ, Rye DB, Wainer BH. The origins of cholinergic and other subcortical afferents to the thalamus in the rat. J Comp Neurol 1987;262:105-24. (Pubitemid 17106949)
17. Williams JA, Comisarow J, Day J, Fibiger HC, Reiner PB. State-dependent release of acetylcholine in rat thalamus measured by in vivo micro-dialysis. J Neurosci 1994;14:5236-42. (Pubitemid 24279046)
18. Marrosu F, Portas C, Mascia MS, et al. Microdialysis measurement of cortical and hippocampal acetylcholine release during sleep-wake cycle in freely moving cats. Brain Res 1995;671:329-32.
19. Yamamoto KI, Domino EF. Cholinergic agonist-antagonist interactions on neocortical and limbic EEG activation. Int J Neuropharmacol 1967;6:357-73.
20. Davila DG, Hurt RD, Offord KP, Harris CD, Shepard JW Jr. Acute effects of transdermal nicotine on sleep architecture, snoring, and sleep-disordered breathing in nonsmokers. Am J Respir Crit Care Med 1994;150:469-74. (Pubitemid 24252360)
21. Spehlmann R, Norcross K. Cholinergic mechanisms in the production of focal cortical slow waves. Experientia 1982;38:109-11. (Pubitemid 12178958)
22. Vanderwolf CH. Neocortical and hippocampal activation relation to behavior: effects of atropine, eserine, phenothiazines, and amphetamine. J Comp Physiol Psychol 1975;88:300-23.
23. Foote SL, Aston-Jones G, Bloom FE. Impulse activity of locus coeruleus neurons in awake rats and monkeys is a function of sensory stimulation and arousal. Proc Natl Acad Sci U S A 1980;77:3033-7. (Pubitemid 10031725)
24. Aston-Jones G, Bloom FE. Activity of norepinephrine-containing locus coeruleus neurons in behaving rats anticipates fluctuations in the sleep-waking cycle. J Neurosci 1981;1:876-86. (Pubitemid 11025876)
25. Berridge CW, Abercrombie ED. Relationship between locus coeruleus discharge rates and rates of norepinephrine release within neocortex as assessed by in vivo microdialysis. Neuroscience 1999;93:1263-70.
26. España RA, Vlasaty J, McCormack SL, Llewellyn-Smith IJ, Scammell TE. Aminergic inputs to the hypocretin/orexin neurons. Society for Neuroscience Meeting, Washington, DC, 2005.
27. Berridge CW, Isaac SO, España RA. Additive wake-promoting actions of medial basal forebrain noradrenergic alpha1- and beta-receptor stimulation. Behav Neurosci 2003;117:350-9. (Pubitemid 36384253)
28. De Sarro GB, Ascioti C, Froio F, Libri V, Nistico G. Evidence that locus coeruleus is the site where clonidine and drugs acting at alpha 1- and alpha 2-adrenoceptors affect sleep and arousal mechanisms. Br J Pharmacol 1987;90:675-85. (Pubitemid 17099401)
29. Berridge CW, Foote SL. Effects of locus coeruleus activation on electroencephalographic activity in neocortex and hippocampus. J Neurosci 1991;11:3135-45.
30. Berridge CW, Page ME, Valentino RJ, Foote SL. Effects of locus coeruleus inactivation on electroencephalographic activity in neocortex and hippocampus. Neuroscience 1993;55:381-93. (Pubitemid 23211350)
31. Berridge CW, España RA. Synergistic sedative effects of noradrenergic alpha(1)- and beta- receptor blockade on forebrain electroencephalo-graphic and behavioral indices. Neuroscience 2000;99:495-505. (Pubitemid 30612452)
32. Aston-Jones G, Rajkowski J, Kubiak P, Alexinsky T. Locus coeruleus neurons in monkey are selectively activated by attended cues in a vigilance task. J Neurosci 1994;14:4467-80. (Pubitemid 24200566)
33. Aston-Jones G, Cohen JD. An integrative theory of locus coeruleus-nor-epinephrine function: adaptive gain and optimal performance. Annu Rev Neurosci 2005;28:403-50. (Pubitemid 41098911)
34. Dayas CV, Buller KM, Crane JW, Xu Y, Day TA. Stressor categorization: acute physical and psychological stressors elicit distinctive recruitment patterns in the amygdala and in medullary noradrenergic cell groups. Eur J Neurosci 2001;14:1143-52. (Pubitemid 35463758)
35. Hunsley MS, Palmiter RD. Norepinephrine-deficient mice exhibit normal sleep-wake states but have shorter sleep latency after mild stress and low doses of amphetamine. Sleep 2003;26:521-6. (Pubitemid 39610643)
36. Gompf HS, Mathai C, Fuller PM, et al. Locus ceruleus and anterior cingulate cortex sustain wakefulness in a novel environment. J Neurosci 2010;30:14543-51.
37. Byers MG, Allison KM, Wendel CS, Lee JK. Prazosin versus quetiapine for nighttime posttraumatic stress disorder symptoms in veterans: an assessment of long-term comparative effectiveness and safety. J Clin Psychopharmacol 2010;30:225-9.
38. Haas HL, Sergeeva OA, Selbach O. Histamine in the nervous system. Physiol Rev 2008;88:1183-241.
39. Sakai K, el Mansari M, Lin JS, Zhang ZG, Vanni-Mercier G. The posterior hypothalamus in the regulation of wakefulness and paradoxical sleep. In: Mancia M, Marini M, eds. The diencephalon and sleep. New York: Raven Press, 1990:171-98.
40. Mochizuki T, Yamatodani A, Okakura K, Horii A, Inagaki N, Wada H. Circadian rhythm of histamine release from the hypothalamus of freely moving rats. Physiol Behav 1992;51:391-4.
41. Lin JS, Sakai K, Jouvet M. Evidence for histaminergic arousal mechanisms in the hypothalamus of cat. Neuropharmacology 1988;27:111-22. (Pubitemid 18052351)
42. Monti JM, Pellejero T, Jantos H. Effects of H1- and H2-histamine receptor agonists and antagonists on sleep and wakefulness in the rat. J Neural Transm 1986;66:1-11. (Pubitemid 16011942)
43. Roehrs TA, Tietz EI, Zorick FJ, Roth T. Daytime sleepiness and antihistamines. Sleep 1984;7:137-41. (Pubitemid 14081937)
44. Tasaka K, Chung YH, Sawada K, Mio M. Excitatory effect of histamine on the arousal system and its inhibition by H1 blockers. Brain Res Bull 1989;22:271-5. (Pubitemid 19165310)
45. Hajak G, Rodenbeck A, Voderholzer U, et al. Doxepin in the treatment of primary insomnia: a placebo-controlled, double-blind, polysomnographic study. J Clin Psychiatry 2001;62:453-63. (Pubitemid 32717879)
46. Krystal AD, Durrence HH, Scharf M, et al. Efficacy and safety of doxepin 1 mg and 3 mg in a 12-week sleep laboratory and outpatient trial of elderly subjects with chronic primary insomnia. Sleep 2010;33:1553-61.
47. Celanire S, Wijtmans M, Talaga P, Leurs R, de Esch IJ. Keynote review: histamine H3 receptor antagonists reach out for the clinic. Drug Discov Today 2005;10:1613-27. (Pubitemid 41817610)
48. Lin JS, Sergeeva OA, Haas HL. Histamine H3 receptors and sleep-wake regulation. J Pharmacol Exp Ther 2011;336:17-23.
49. Kanbayashi T, Kodama T, Kondo H, et al. CSF histamine contents in narcolepsy, idiopathic hypersomnia and obstructive sleep apnea syndrome. Sleep 2009;32:181-7.
50. Lin JS, Sakai K, Vanni-Mercier G, et al. Involvement of histaminergic neurons in arousal mechanisms demonstrated with H3-receptor ligands in the cat. Brain Res 1990;523:325-30. (Pubitemid 20230168)
51. Monti JM, Jantos H, Ponzoni A, Monti D. Sleep and waking during acute histamine H3 agonist BP 2.94 or H3 antagonist carboperamide (MR 16155) administration in rats. Neuropsychopharmacology 1996;15:31-5. (Pubitemid 26233388)
52. Bonaventure P, Letavic M, Dugovic C, et al. Histamine H3 receptor antagonists: from target identification to drug leads. Biochem Pharmacol 2007;73:1084-96. (Pubitemid 46413171)
53. Ligneau X, Perrin D, Landais L, et al. BF2.649 [1-{3-[3-(4-Chlorophenyl) propoxy] propyl}piperidine, hydrochloride], a nonimidazole inverse agonist/antagonist at the human histamine H3 receptor: Preclinical pharmacology. J Pharmacol Exp Ther 2007;320:365-75. (Pubitemid 46025751)
54. Lin JS, Dauvilliers Y, Arnulf I, et al. An inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin-/- mice and patients. Neurobiol Dis 2008;30:74-83.
55. Huang ZL, Mochizuki T, Qu WM, et al. Altered sleep-wake characteristics and lack of arousal response to H3 receptor antagonist in histamine H1 receptor knockout mice. Proc Natl Acad Sci U S A 2006;103:4687-92.
56. van RP, Vermeeren A, Riedel WJ. Cognitive domains affected by histamine H(1)-antagonism in humans: a literature review. Brain Res Rev 2010;64:263-82.
57. Passani MB, Blandina P, Torrealba F. The histamine H3 receptor and eating behavior. J Pharmacol Exp Ther 2011;336:24-9.
58. Parmentier R, Ohtsu H, Djebbara-Hannas Z, Valatx JL, Watanabe T, Lin JS. Anatomical, physiological, and pharmacological characteristics of histidine decarboxylase knock-out mice: evidence for the role of brain histamine in behavioral and sleep-wake control. J Neurosci 2002;22:7695-711. (Pubitemid 35386369)
59. Trulson ME, Jacobs BL. Raphe unit activity in freely moving cats: correlation with level of behavioral arousal. Brain Res 1979;163:135-50. (Pubitemid 9111292)
60. Portas CM, Bjorvatn B, Fagerland S, et al. On-line detection of extracellular levels of serotonin in dorsal raphe nucleus and frontal cortex over the sleep/wake cycle in the freely moving rat. Neuroscience 1998;83:807-14. (Pubitemid 28068901)
61. Dzoljic MR, Ukponmwan OE, Saxena PR. 5-HT1-like receptor agonists enhance wakefulness. Neuropharmacology 1992;31:623-33.
62. Dugovic C, Wauquier A, Leysen JE, Marrannes R, Janssen PA. Functional role of 5-HT2 receptors in the regulation of sleep and wakefulness in the rat. Psychopharmacology (Berl) 1989;97:436-42. (Pubitemid 19102542)
63. Bjorvatn B, Ursin R. Effects of the selective 5-HT1B agonist, CGS 12066B, on sleep/waking stages and EEG power spectrum in rats. J Sleep Res 1994;3:97-105.
64. Boutrel B, Franc B, Hen R, Hamon M, Adrien J. Key role of 5-HT1B receptors in the regulation of paradoxical sleep as evidenced in 5-HT1B knock-out mice. J Neurosci 1999;19:3204-12. (Pubitemid 29174012)
65. Ponzoni A, Monti JM, Jantos H. The effects of selective activation of the 5-HT3 receptor with m-chlorophenylbiguanide on sleep and wakefulness in the rat. Eur J Pharmacol 1993;249:259-64. (Pubitemid 23334098)
66. Bakalian MJ, Fernstrom JD. Effects of L-tryptophan and other amino acids on electroencephalographic sleep in the rat. Brain Res 1990;528:300-7. (Pubitemid 20318209)
67. Maudhuit C, Jolas T, Lainey E, Hamon M, Adrien J. Effects of acute and chronic treatment with amoxapine and cericlamine on the sleep-wakefulness cycle in the rat. Neuropharmacology 1994;33:1017-25.
68. Vasar V, Appelberg B, Rimon R, Selvaratnam J. The effect of fluoxetine on sleep: a longitudinal, double-blind polysomnographic study of healthy volunteers. Int Clin Psychopharmacol 1994;9:203-6. (Pubitemid 24317184)
69. Monaca C, Boutrel B, Hen R, Hamon M, Adrien J. 5-HT 1A/1B receptor-mediated effects of the selective serotonin reuptake inhibitor, citalopram, on sleep: studies in 5-HT 1A and 5-HT 1B knockout mice. Neuropsychopharmacology 2003;28:850-6.
70. Vazquez-Palacios G, Hernandez-Gonzalez M, Guevara Perez MA, Bonilla-Jaime H. Nicotine and fluoxetine induce arousing effects on sleep-wake cycle in antidepressive doses: a possible mechanism of antidepressant-like effects of nicotine. Pharmacol Biochem Behav 2010;94:503-9.
71. Monti JM. Serotonin 5-HT(2A) receptor antagonists in the treatment of insomnia: present status and future prospects. Drugs Today (Barc) 2010;46:183-93.
72. Teegarden BR, Al SH, Xiong Y. 5-HT(2A) inverse-agonists for the treatment of insomnia. Curr Top Med Chem 2008;8:969-76.
73. Lemoine P, Guilleminault C, Alvarez E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. J Clin Psychiatry 2007;68:1723-32. (Pubitemid 350247502)
74. Neylan TC, van Kammen DP, Kelley ME, Peters JL. Sleep in schizophrenic patients on and off haloperidol therapy. Clinically stable vs relapsed patients. Arch Gen Psychiatry 1992;49:643-9.
75. Ongini E, Bonizzoni E, Ferri N, Milani S, Trampus M. Differential effects of dopamine D-1 and D-2 receptor antagonist antipsychotics on sleep-wake patterns in the rat. J Pharmacol Exp Ther 1993;266:726-31. (Pubitemid 23318684)
76. Arnulf I, Leu S, Oudiette D. Abnormal sleep and sleepiness in Parkinson's disease. Curr Opin Neurol 2008;21:472-7.
77. Paus S, Brecht HM, Koster J, Seeger G, Klockgether T, Wullner U. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease. Mov Disord 2003;18:659-67. (Pubitemid 36790281)
78. Arnulf I. Excessive daytime sleepiness in parkinsonism. Sleep Med Rev 2005;9:185-200. (Pubitemid 40694186)
79. Schultz W. Predictive reward signal of dopamine neurons. J Neurophysiol 1998;80:1-27. (Pubitemid 28326237)
80. Schultz W. Multiple dopamine functions at different time courses. Annu Rev Neurosci 2007;30:259-88. (Pubitemid 47218758)
81. Trulson ME. Simultaneous recording of substantia nigra neurons and voltammetric release of dopamine in the caudate of behaving cats. Brain Res Bull 1985;15:221-3. (Pubitemid 15017264)
82. Trulson ME, Preussler DW. Dopamine-containing ventral tegmental area neurons in freely moving cats: activity during the sleep-waking cycle and effects of stress. Exp Neurol 1984;83:367-77. (Pubitemid 14192314)
83. Lu J, Jhou TC, Saper CB. Identification of wake-active dopaminergic neurons in the ventral periaqueductal gray matter. J Neurosci 2006;26:193-202. (Pubitemid 43089532)
84. Schmitt KC, Reith ME. Regulation of the dopamine transporter: aspects relevant to psychostimulant drugs of abuse. Ann N Y Acad Sci 2010;1187:316-40.
85. Volkow ND, Fowler JS, Logan J, et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA 2009;301:1148-54.
86. Mignot E, Nishino S, Guilleminault C, Dement WC. Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep 1994;17:436-7. (Pubitemid 24271517)
87. Wisor JP, Nishino S, Sora I, Uhl GH, Mignot E, Edgar DM. Dopaminergic role in stimulant-induced wakefulness. J Neurosci 2001;21:1787-94. (Pubitemid 32184295)
88. Qu WM, Huang ZL, Xu XH, Matsumoto N, Urade Y. Dopaminergic D1 and D2 receptors are essential for the arousal effect of modafinil. J Neurosci 2008;28:8462-9.
89. Sakurai T, Amemiya A, Ishii M, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998;92:1.
90. de Lecea L, Kilduff TS, Peyron C, et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci U S A 1998;95:322-7. (Pubitemid 28103952)
91. Peyron C, Tighe DK, van Den Pol AN, et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci 1998;18:9996-10015. (Pubitemid 28543775)
92. Mileykovskiy BY, Kiyashchenko LI, Siegel JM. Behavioral correlates of activity in identified hypocretin/orexin neurons. Neuron 2005;46:787-98. (Pubitemid 40733133)
93. Lee MG, Hassani OK, Jones BE. Discharge of identified orexin/hypocretin neurons across the sleep-waking cycle. J Neurosci 2005;25:6716-20. (Pubitemid 40995304)
94. Zeitzer JM, Buckmaster CL, Parker KJ, Hauck CM, Lyons DM, Mignot E. Circadian and homeostatic regulation of hypocretin in a primate model: implications for the consolidation of wakefulness. J Neurosci 2003;23:3555-60. (Pubitemid 36531999)
95. Hagan JJ, Leslie RA, Patel S, et al. Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proc Natl Acad Sci U S A 1999;96:10911-6. (Pubitemid 29442243)
96. Bourgin P, Huitron-Resendiz S, Spier AD, et al. Hypocretin-1 modulates rapid eye movement sleep through activation of locus coeruleus neurons. J Neurosci 2000;20:7760-5.
97. España RA, Baldo BA, Kelley AE, Berridge CW. Wake-promoting and sleep-suppressing actions of hypocretin (orexin): basal forebrain sites of action. Neuroscience 2001;106:699-715. (Pubitemid 33000176)
98. Adamantidis AR, Zhang F, Aravanis AM, Deisseroth K, de Lecea L. Neural substrates of awakening probed with optogenetic control of hypocretin neurons. Nature 2007;450:420-4. (Pubitemid 350126754)
99. Carter ME, Adamantidis A, Ohtsu H, Deisseroth K, de Lecea L. Sleep homeostasis modulates hypocretin-mediated sleep-to-wake transitions. J Neurosci 2009;29:10939-49.
100. Brisbare-Roch C, Dingemanse J, Koberstein R, et al. Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat Med 2007;13:150-5.
101. Dugovic C, Shelton JE, Aluisio LE, et al. Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat. J Pharmacol Exp Ther 2009;330:142-51.
102. Scammell TE, Winrow CJ. Orexin receptors: pharmacology and therapeutic opportunities. Annu Rev Pharmacol Toxicol 2011;51:243-66.
103. Chemelli RM, Willie JT, Sinton CM, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 1999;98:437-51. (Pubitemid 29402482)
104. Lin L, Faraco J, Li R, et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999;98:365-76. (Pubitemid 29380571)
105. Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 2000;355:39-40. (Pubitemid 30072183)
106. Peyron C, Faraco J, Rogers W, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000;6:991-7.
107. Thannickal TC, Moore RY, Nienhuis R, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000;27:469-74.
108. España RA, McCormack SL, Mochizuki T, Scammell TE. Running promotes wakefulness and increases cataplexy in orexin knockout mice. Sleep 2007;30:1417-25. (Pubitemid 350036969)
109. Hara J, Beuckmann CT, Nambu T, et al. Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 2001;30:345-54. (Pubitemid 32530580)
110. Mochizuki T, Crocker A, McCormack S, Yanagisawa M, Sakurai T, Scammell TE. Behavioral state instability in orexin knock-out mice. J Neurosci 2004;24:6291-300. (Pubitemid 38944219)
111. Scammell TE, Willie JT, Guilleminault C, Siegel JM. A consensus definition of cataplexy in mouse models of narcolepsy. Sleep 2009;32:111-6.
112. Crocker A, Espana RA, Papadopoulou M, et al. Concomitant loss of dynorphin, NARP, and orexin in narcolepsy. Neurology 2005;65:1184-8.
113. Thannickal TC, Lai YY, Siegel JM. Hypocretin (orexin) cell loss in Parkinson's disease. Brain 2007;130:1586-95. (Pubitemid 47355933)
114. Fronczek R, Overeem S, Lee SY, et al. Hypocretin (orexin) loss in Parkinson's disease. Brain 2007;130:1577-85. (Pubitemid 47355929)
115. Benarroch EE, Schmeichel AM, Sandroni P, Low PA, Parisi JE. Involvement of hypocretin neurons in multiple system atrophy. Acta Neuropathol 2007;113:75-80. (Pubitemid 44782931)
116. Baumann CR, Bassetti CL, Valko PO, et al. Loss of hypocretin (orexin) neurons with traumatic brain injury. Ann Neurol 2009;66:555-9.
117. Fronczek R, Baumann CR, Lammers GJ, Bassetti CL, Overeem S. Hypocretin/ orexin disturbances in neurological disorders. Sleep Med Rev 2009;13:9-22.
118. Borgland SL, Chang SJ, Bowers MS, et al. Orexin A/hypocretin-1 selectively promotes motivation for positive reinforcers. J Neurosci 2009;29:11215-25.
119. Aston-Jones G, Smith RJ, Moorman DE, Richardson KA. Role of lateral hypothalamic orexin neurons in reward processing and addiction. Neuropharmacology 2009;56 Suppl 1:112-21.
120. España RA, Oleson EB, Locke JL, Brookshire BR, Roberts DCS, Jones SR. The hypocretin-orexin system regulates cocaine self-administration via actions on the mesolimbic dopamine system. Eur J Neurosci 2010;31:336-48.
121. España RA, Melchior JR, Roberts DCS, Jones SR. Hypocretin 1/orexin A in the ventral tegmental area enhances dopamine responses to cocaine and promotes cocaine self-administration. Psychopharmacology 2010;1-12.
122. Moriguchi T, Sakurai T, Nambu T, Yanagisawa M, Goto K. Neurons containing orexin in the lateral hypothalamic area of the adult rat brain are activated by insulin-induced acute hypoglycemia. Neurosci Lett 1999;264:101-4. (Pubitemid 29195959)
123. Burdakov D, Gerasimenko O, Verkhratsky A. Physiological changes in glucose differentially modulate the excitability of hypothalamic melanin-concentrating hormone and orexin neurons in situ. J Neurosci 2005;25:2429-33. (Pubitemid 40322285)
124. Yamanaka A, Beuckmann CT, Willie JT, et al. Hypothalamic orexin neurons regulate arousal according to energy balance in mice. Neuron 2003;38:701-13. (Pubitemid 36694778)
125. McCormick DA, Bal T. Sleep and arousal: thalamocortical mechanisms. Annu Rev Neurosci 1997;20:185-215. (Pubitemid 27106380)
126. Huguenard JR, McCormick DA. Thalamic synchrony and dynamic regulation of global forebrain oscillations. Trends Neurosci 2007;30:350-6. (Pubitemid 46991122)
127. Steriade M, Domich L, Oakson G, Deschenes M. The deafferented reticular thalamic nucleus generates spindle rhythmicity. J Neurophysiol 1987;57:260-73. (Pubitemid 17036266)
128. Livingstone MS, Hubel DH. Effects of sleep and arousal on the processing of visual information in the cat. Nature 1981;291:554-61. (Pubitemid 11043678)
129. Hu B, Steriade M, Deschenes M. The cellular mechanism of thalamic ponto-geniculo-occipital waves. Neuroscience 1989;31:25-35. (Pubitemid 19209696)
130. Vanderwolf CH, Robinson TE. Reticulo-cortical activity and behavior: A critique of the arousal theory and a new synthesis. Behavioral Brain Science 1981;4:459-514. (Pubitemid 12228137)
131. Buzsaki G, Bickford RG, Ponomareff G, Thal LJ, Mandel R, Gage FH. Nucleus basalis and thalamic control of neocortical activity in the freely moving rat. J Neurosci 1988;8:4007-26. (Pubitemid 19017388)
132. Kinney HC, Korein J, Panigrahy A, Dikkes P, Goode R. Neuropathological findings in the brain of Karen Ann Quinlan. The role of the thalamus in the persistent vegetative state. N Engl J Med 1994;330:1469-75.
133. Fuller P, Sherman D, Pedersen NP, Saper CB, Lu J. Reassessment of the structural basis of the ascending arousal system. J Comp Neurol 2011;519:933-56.
134. Gerashchenko D, Wisor JP, Burns D, et al. Identification of a population of sleep-active cerebral cortex neurons. Proc Natl Acad Sci U S A 2008;105:10227-32.
135. Vyazovskiy VV, Cirelli C, Pfister-Genskow M, Faraguna U, Tononi G. Molecular and electrophysiological evidence for net synaptic potentiation in wake and depression in sleep. Nat Neurosci 2008;11:200-8. (Pubitemid 351170495)
136. Huber R, Ghilardi MF, Massimini M, Tononi G. Local sleep and learning. Nature 2004;430:78-81. (Pubitemid 38915227)
137. Huber R, Ghilardi MF, Massimini M, et al. Arm immobilization causes cortical plastic changes and locally decreases sleep slow wave activity. Nat Neurosci 2006;9:1169-76. (Pubitemid 44306311)
138. Pfaff D, Banavar JR. A theoretical framework for CNS arousal. Bioessays 2007;29:803-10. (Pubitemid 47204285)
139. Sherin JE, Shiromani PJ, McCarley RW, Saper CB. Activation of ventro-lateral preoptic neurons during sleep. Science 1996;271:216-9.
140. Gong H, McGinty D, Guzman-Marin R, Chew KT, Stewart D, Szymusiak R. Activation of c-fos in GABAergic neurones in the preoptic area during sleep and in response to sleep deprivation. J Physiol 2004;556:935-46. (Pubitemid 38660324)
141. Szymusiak R, Alam N, Steininger TL, McGinty D. Sleep-waking discharge patterns of ventrolateral preoptic/anterior hypothalamic neurons in rats. Brain Res 1998;803:178-88. (Pubitemid 28392144)
142. Takahashi K, Lin JS, Sakai K. Characterization and mapping of sleep-waking specific neurons in the basal forebrain and preoptic hypothalamus in mice. Neuroscience 2009;161:269-92.
143. Suntsova N, Szymusiak R, Alam MN, Guzman-Marin R, McGinty D. Sleep-waking discharge patterns of median preoptic nucleus neurons in rats. J Physiol 2002;543:665-77. (Pubitemid 35012218)
144. McGinty DJ, Sterman MB. Sleep suppression after basal forebrain lesions in the cat. Science 1968;160:1253-5.
145. Lu J, Greco MA, Shiromani P, Saper CB. Effect of lesions of the ventrolateral preoptic nucleus on NREM and REM sleep. J Neurosci 2000;20:3830-42. (Pubitemid 30266244)
146. Sherin JE, Elmquist JK, Torrealba F, Saper CB. Innervation of histaminergic tuberomammillary neurons by GABAergic and galaninergic neurons in the ventrolateral preoptic nucleus of the rat. J Neurosci 1998;18:4705-21. (Pubitemid 28280179)
147. Gaus SE, Strecker RE, Tate BA, Parker RA, Saper CB. Ventrolateral preoptic nucleus contains sleep-active, galaninergic neurons in multiple mammalian species. Neuroscience 2002;115:285-94. (Pubitemid 35232707)
148. Saper CB, Cano G, Scammell TE. Homeostatic, circadian, and emotional regulation of sleep. J Comp Neurol 2005;493:92-8. (Pubitemid 41636191)
149. Saper CB, Fuller PM, Pedersen NP, Lu J, Scammell TE. Sleep state switching. Neuron 2010;68:1023-42.
150. Manns ID, Alonso A, Jones BE. Discharge profiles of juxtacellularly labeled and immunohistochemically identified GABAergic basal forebrain neurons recorded in association with the electroencephalogram in anesthetized rats. J Neurosci 2000;20:9252-63. (Pubitemid 32042928)
151. Hassani OK, Lee MG, Henny P, Jones BE. Discharge profiles of identified GABAergic in comparison to cholinergic and putative glutamatergic basal forebrain neurons across the sleep-wake cycle. J Neurosci 2009;29:11828-40.
152. Hassani OK, Henny P, Lee MG, Jones BE. GABAergic neurons intermingled with orexin and MCH neurons in the lateral hypothalamus discharge maximally during sleep. Eur J Neurosci 2010;32:448-57.
153. Gottesmann C. GABA mechanisms and sleep. Neuroscience 2002;111:231-9. (Pubitemid 34442609)
154. Sanger DJ. The pharmacology and mechanisms of action of new generation, non-benzodiazepine hypnotic agents. CNS Drugs 2004;18 Suppl 1:9-15. (Pubitemid 38626399)
155. Vienne J, Bettler B, Franken P, Tafti M. Differential effects of GABAB receptor subtypes, {gamma}-hydroxybutyric Acid, and Baclofen on EEG activity and sleep regulation. J Neurosci 2010;30:14194-204.
156. Steriade M, Datta S, Pare D, Oakson G, Curro Dossi RC. Neuronal activities in brain-stem cholinergic nuclei related to tonic activation processes in thalamocortical systems. J Neurosci 1990;10:2541-59.
157. Kayama Y, Ohta M, Jodo E. Firing of 'possibly' cholinergic neurons in the rat laterodorsal tegmental nucleus during sleep and wakefulness. Brain Res 1992;569:210-20.
158. Boissard R, Gervasoni D, Schmidt MH, Barbagli B, Fort P, Luppi PH. The rat ponto-medullary network responsible for paradoxical sleep onset and maintenance: a combined microinjection and functional neuroanatomical study. Eur J Neurosci 2002;16:1959-73. (Pubitemid 37059584)
159. Velazquez-Moctezuma J, Gillin JC, Shiromani PJ. Effect of specific M1, M2 muscarinic receptor agonists on REM sleep generation. Brain Res 1989;503:128-31.
160. Marks GA, Birabil CG. Comparison of three muscarinic agonits injected into the medial pontine reticular formation of rats to enhance REM sleep. Sleep Res Online 2001;4:17-24.
161. Baghdoyan HA. Location and quantification of muscarinic receptor sub-types in rat pons: implications for REM sleep generation. Am J Physiol 1997;273:R896-R904.
162. Imeri L, Bianchi S, Angeli P, Mancia M. Selective blockade of different brain stem muscarinic receptor subtypes: effects on the sleep-wake cycle. Brain Res 1994;636:68-72. (Pubitemid 24035691)
163. Benington JH, Heller HC. Monoaminergic and cholinergic modulation of REM-sleep timing in rats. Brain Res 1995;681:141-6.
164. Webster HH, Jones BE. Neurotoxic lesions of the dorsolateral pontomesencephalic tegmentum-cholinergic cell area in the cat. II. Effects upon sleep-waking states. Brain Res 1988;458:285-302.
165. Shouse MN, Siegel JM. Pontine regulation of REM sleep components in cats: integrity of the pedunculopontine tegmentum (PPT) is important for phasic events but unnecessary for atonia during REM sleep. Brain Res 1992;571:50-63.
166. Morales FR, Engelhardt JK, Soja PJ, Pereda AE, Chase MH. Motoneuron properties during motor inhibition produced by microinjection of carbachol into the pontine reticular formation of the decerebrate cat. J Neurophysiol 1987;57:1118-29. (Pubitemid 17059750)
167. Curtis DR, Hosli L, Johnston GA, Johnston IH. The hyperpolarization of spinal motoneurones by glycine and related amino acids. Exp Brain Res 1968;5:235-58.
168. Chase MH, Soja PJ, Morales FR. Evidence that glycine mediates the
169. Yamuy J, Fung SJ, Xi M, Morales FR, Chase MH. Hypoglossal motoneurons are postsynaptically inhibited during carbachol-induced rapid eye movement sleep. Neuroscience 1999;94:11-5. (Pubitemid 29457591)
170. Fedirchuk B, Dai Y. Monoamines increase the excitability of spinal neurones in the neonatal rat by hyperpolarizing the threshold for action potential production. J Physiol 2004;557:355-61. (Pubitemid 38807382)
171. Jelev A, Sood S, Liu H, Nolan P, Horner RL. Microdialysis perfusion of 5-HT into hypoglossal motor nucleus differentially modulates genioglossus activity across natural sleep-wake states in rats. J Physiol 2001;532:467-81. (Pubitemid 32390403)
172. Perrier JF, Delgado-Lezama R. Synaptic release of serotonin induced by stimulation of the raphe nucleus promotes plateau potentials in spinal motoneurons of the adult turtle. J Neurosci 2005;25:7993-9. (Pubitemid 41254402)
173. Lai YY, Kodama T, Siegel JM. Changes in monoamine release in the ventral horn and hypoglossal nucleus linked to pontine inhibition of muscle tone: an in vivo microdialysis study. J Neurosci 2001;21:7384-91. (Pubitemid 32846985)
174. Morrison JL, Sood S, Liu H, et al. Role of inhibitory amino acids in control of hypoglossal motor outflow to genioglossus muscle in naturally sleeping rats. J Physiol 2003;552:975-91. (Pubitemid 37428435)
175. Fenik V, Davies RO, Kubin L. Combined antagonism of aminergic excitatory and amino acid inhibitory receptors in the XII nucleus abolishes REM sleep-like depression of hypoglossal motoneuronal activity. Arch Ital Biol 2004;142:237-49. (Pubitemid 38796876)
176. Leonard CS, Llinas R. Serotonergic and cholinergic inhibition of mesopontine cholinergic neurons controlling REM sleep: an in vitro electro-physiological study. Neuroscience 1994;59:309-30. (Pubitemid 24098792)
177. McCarley RW, Hobson JA. Neuronal excitability modulation over the sleep cycle: a structural and mathematical model. Science 1975;189:58-60.
178. Hoque R, Chesson AL Jr. Pharmacologically induced/exacerbated restless legs syndrome, periodic limb movements of sleep, and REM behavior disorder/REM sleep without atonia: literature review, qualitative scoring, and comparative analysis. J Clin Sleep Med 2010;6:79-83.
179. Wilson S, Argyropoulos S. Antidepressants and sleep: a qualitative review of the literature. Drugs 2005;65:927-47. (Pubitemid 40663621)
180. Sakai K, Sastre JP, Salvert D, Touret M, Tohyama M, Jouvet M. Tegmentoreticular projections with special reference to the muscular atonia during paradoxical sleep in the cat: an HRP study. Brain Res 1979;176:233-54. (Pubitemid 10220807)
181. Verret L, Leger L, Fort P, Luppi PH. Cholinergic and noncholinergic brainstem neurons expressing Fos after paradoxical (REM) sleep deprivation and recovery. Eur J Neurosci 2005;21:2488-504. (Pubitemid 40813930)
182. Lu J, Sherman D, Devor M, Saper CB. A putative flip-flop switch for control of REM sleep. Nature 2006;441:589-94. (Pubitemid 43927285)
183. Xi MC, Morales FR, Chase MH. Interactions between GABAergic and cholinergic processes in the nucleus pontis oralis: neuronal mechanisms controlling active (rapid eye movement) sleep and wakefulness. J Neurosci 2004;24:10670-8. (Pubitemid 39557640)
184. Sastre JP, Jouvet M. Oneiric behavior in cats. Physiol Behav 1979;22:979-89.
185. Hendricks JC, Morrison AR, Mann GL. Different behaviors during paradoxical sleep without atonia depend on pontine lesion site. Brain Res 1982;239:81-105. (Pubitemid 12101770)
186. Boeve BF, Silber MH, Saper CB, et al. Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. Brain 2007;130:2770-88. (Pubitemid 350033955)
187. Boissard R, Fort P, Gervasoni D, Barbagli B, Luppi PH. Localization of the GABAergic and non-GABAergic neurons projecting to the sublat-erodorsal nucleus and potentially gating paradoxical sleep onset. Eur J Neurosci 2003;18:1627-39. (Pubitemid 37215115)
188. Sastre JP, Buda C, Kitahama K, Jouvet M. Importance of the ventrolateral region of the periaqueductal gray and adjacent tegmentum in the control of paradoxical sleep as studied by muscimol microinjections in the cat. Neuroscience 1996;74:415-26. (Pubitemid 26274212)
189. Alam MN, Gong H, Alam T, Jaganath R, McGinty D, Szymusiak R. Sleep-waking discharge patterns of neurons recorded in the rat perifornical lateral hypothalamic area. J Physiol 2002;538:619-31. (Pubitemid 35175385)
190. Koyama Y, Takahashi K, Kodama T, Kayama Y. State-dependent activity of neurons in the perifornical hypothalamic area during sleep and waking. Neuroscience 2003;119:1209-19. (Pubitemid 36776465)
191. Verret L, Goutagny R, Fort P, et al. A role of melanin-concentrating hormone producing neurons in the central regulation of paradoxical sleep. BMC Neurosci 2003;4:19.
192. Bittencourt JC, Presse F, Arias C, et al. The melanin-concentrating hormone system of the rat brain: an immuno- and hybridization histochemical characterization. J Comp Neurol 1992;319:218-45.
193. Kilduff TS, de Lecea L. Mapping of the mRNAs for the hypocretin/orexin and melanin- concentrating hormone receptors: Networks of overlapping peptide systems. J Comp Neurol 2001;435:1-5. (Pubitemid 32448718)
194. Ahnaou A, Drinkenburg WH, Bouwknecht JA, Alcazar J, Steckler T, Dautzenberg FM. Blocking melanin-concentrating hormone MCH1 receptor affects rat sleep-wake architecture. Eur J Pharmacol 2008;579:177-88.
195. Willie JT, Sinton CM, Maratos-Flier E, Yanagisawa M. Abnormal response of melanin-concentrating hormone deficient mice to fasting: hyperactivity and rapid eye movement sleep suppression. Neuroscience 2008;156:819-29.
196. Chou TC, Bjorkum AA, Gaus SE, Lu J, Scammell TE, Saper CB. Afferents to the ventrolateral preoptic nucleus. J Neurosci 2002;22:977-90. (Pubitemid 34141777)
197. Gallopin T, Fort P, Eggermann E, et al. Identification of sleep-promoting neurons in vitro. Nature 2000;404:992-5. (Pubitemid 30243592)
198. Brown RE, Sergeeva O, Eriksson KS, Haas HL. Orexin A excites serotonergic neurons in the dorsal raphe nucleus of the rat. Neuropharmacology 2001;40:457-9. (Pubitemid 32144724)
199. Eggermann E, Serafin M, Bayer L, et al. Orexins/hypocretins excite basal forebrain cholinergic neurones. Neuroscience 2001;108:177-81. (Pubitemid 33152961)
200. Marcus JN, Aschkenasi CJ, Lee CE, et al. Differential expression of orexin receptors 1 and 2 in the rat brain. J Comp Neurol 2001;435:6-25. (Pubitemid 32448719)
201. Arrigoni E, Saper CB, Lu J. Modulation of the spinal cord projecting neurons of the sublaterodorsal nucleus. Society for Neuroscience Meeting, Chicago, IL, 2009.
202. Broughton R, Valley V, Aguirre M, Roberts J, Suwalski W, Dunham W. Excessive daytime sleepiness and the pathophysiology of narcolepsy-cataplexy: a laboratory perspective. Sleep 1986;9:205-15. (Pubitemid 18008497)
203. Ishimori K. True cause of sleep: A hypnogenic substance as evidenced in the brain of sleep-deprived animals. Tokyo Igakkai Zasshi 1909;23:429-57.
204. Legendre R, Pieron H. Recherches sur le besoin de sommeil consecutif à une veille prolongée. Z Allgem Physiol 1913;14:235-62.
205. Obal F, Jr., Krueger JM. Biochemical regulation of non-rapid-eye-movement sleep. Front Biosci 2003;8:d520-d550. (Pubitemid 38943208)
206. Radulovacki M, Virus RM, Djuricic-Nedelson M, Green RD. Adenosine analogs and sleep in rats. J Pharmacol Exp Ther 1984;228:268-74. (Pubitemid 14190729)
207. Benington JH, Kodali SK, Heller HC. Stimulation of A1 adenosine receptors mimics the electroencephalographic effects of sleep deprivation. Brain Res 1995;692:79-85.
208. Basheer R, Strecker RE, Thakkar MM, McCarley RW. Adenosine and sleep-wake regulation. Prog Neurobiol 2004;73:379-96. (Pubitemid 39094087)
209. Porkka-Heiskanen T, Strecker RE, Thakkar M, Bjorkum AA, Greene RW, McCarley RW. Adenosine: a mediator of the sleep-inducing effects of prolonged wakefulness. Science 1997;276:1265-8.
210. Halassa MM, Florian C, Fellin T, et al. Astrocytic modulation of sleep homeostasis and cognitive consequences of sleep loss. Neuron 2009;61:213-9.
211. Huang ZL, Urade Y, Hayaishi O. Prostaglandins and adenosine in the regulation of sleep and wakefulness. Curr Opin Pharmacol 2007;7:33-8. (Pubitemid 46238038)
212. Oishi Y, Huang ZL, Fredholm BB, Urade Y, Hayaishi O. Adenosine in the tuberomammillary nucleus inhibits the histaminergic system via A1 receptors and promotes non-rapid eye movement sleep. Proc Natl Acad Sci U S A 2008;105:19992-7.
213. Scammell TE, Gerashchenko DY, Mochizuki T, et al. An adenosine A2a agonist increases sleep and induces Fos in ventrolateral preoptic neurons. Neuroscience 2001;107:653-63. (Pubitemid 33097501)
214. Penetar D, McCann U, Thorne D, et al. Caffeine reversal of sleep deprivation effects on alertness and mood. Psychopharmacology (Berl) 1993;112:359-65. (Pubitemid 23278301)
215. Imeri L, Opp MR. How (and why) the immune system makes us sleep. Nat Rev Neurosci 2009;10:199-210.
216. Alam MN, McGinty D, Bashir T, et al. Interleukin-1beta modulates state-dependent discharge activity of preoptic area and basal forebrain neurons: role in sleep regulation. Eur J Neurosci 2004;20:207-16. (Pubitemid 38932141)
217. Kubota T, Li N, Guan Z, Brown RA, Krueger JM. Intrapreoptic microinjection of TNF-alpha enhances non-REM sleep in rats. Brain Res 2002;932:37-44. (Pubitemid 34241592)
218. Krueger JM, Majde JA. Microbial products and cytokines in sleep and fever regulation. Crit Rev Immunol 1994;14:355-79.
219. Bredow S, Guha-Thakurta N, Taishi P, Obal F, Jr., Krueger JM. Diurnal variations of tumor necrosis factor alpha mRNA and alpha-tubulin mRNA in rat brain. Neuroimmunomodulation 1997;4:84-90. (Pubitemid 28004890)
220. Floyd RA, Krueger JM. Diurnal variation of TNF alpha in the rat brain. Neuroreport 1997;8:915-8. (Pubitemid 27152146)
221. Taishi P, Bredow S, Guha-Thakurta N, Obal F, Jr., Krueger JM. Diurnal variations of interleukin-1 beta mRNA and beta-actin mRNA in rat brain. J Neuroimmunol 1997;75:69-74. (Pubitemid 27170304)
222. Mizoguchi A, Eguchi N, Kimura K, et al. Dominant localization of prostaglandin D receptors on arachnoid trabecular cells in mouse basal fore-brain and their involvement in the regulation of non-rapid eye movement sleep. Proc Natl Acad Sci U S A 2001;98:11674-9. (Pubitemid 32928787)
223. Pandey HP, Ram A, Matsumura H, Satoh S, Hayaishi O. Circadian variations of prostaglandins D2, E2, and F2 alpha in the cerebrospinal fluid of anesthetized rats. Biochem Biophys Res Commun 1995;213:625-9.
224. Ram A, Pandey HP, Matsumura H, et al. CSF levels of prostaglandins, especially the level of prostaglandin D2, are correlated with increasing propensity towards sleep in rats. Brain Res 1997;751:81-9. (Pubitemid 27122138)
225. Scammell T, Gerashchenko D, Urade Y, Onoe H, Saper C, Hayaishi O. Activation of ventrolateral preoptic neurons by the somnogen prostaglandin D2. Proc Natl Acad Sci U S A 1998;95:7754-9. (Pubitemid 28293326)
226. Ueno R, Honda K, Inoue S, Hayaishi O. Prostaglandin D2, a cerebral sleep-inducing substance in rats. Proc Natl Acad Sci U S A 1983;80:1735-7.
227. Inoue S, Honda K, Komoda Y, Uchizono K, Ueno R, Hayaishi O. Differential sleep-promoting effects of five sleep substances nocturnally infused in unrestrained rats. Proc Natl Acad Sci U S A 1984;81:6240-4. (Pubitemid 15220816)
228. Onoe H, Ueno R, Fujita I, Nishino H, Oomura Y, Hayaishi O. Prostaglandin D2, a cerebral sleep-inducing substance in monkeys. Proc Natl Acad Sci U S A 1988;85:4082-6.
229. Kantha SS. Histamine-interleukin-prostaglandin pathway: a hypothesis for a biochemical cycle regulating sleep and wakefulness. Med Hypotheses 1994;42:335-9.
230. Pentreath VW, Rees K, Owolabi OA, Philip KA, Doua F. The somnogenic T lymphocyte suppressor prostaglandin D2 is selectively elevated in cerebrospinal fluid of advanced sleeping sickness patients. Trans R Soc Trop Med Hyg 1990;84:795-9.
231. Borbely AA, Achermann P. Sleep homeostasis and models of sleep regulation. J Biol Rhythms 1999;14:557-68. (Pubitemid 30086864)
232. Achermann P. The two-process model of sleep regulation revisited. Aviat Space Environ Med 2004;75:A37-A43. (Pubitemid 38269609)
233. Dijk DJ, Czeisler CA. Contribution of the circadian pacemaker and the sleep homeostat to sleep propensity, sleep structure, electroencephalographic slow waves, and sleep spindle activity in humans. J Neurosci 1995;15:3526-38.
234. Dijk DJ, Brunner DP, Borbely AA. Time course of EEG power density during long sleep in humans. Am J Physiol 1990;258:R650-R661. (Pubitemid 20103281)
235. Franken P, Dijk DJ, Tobler I, Borbely AA. Sleep deprivation in rats: effects on EEG power spectra, vigilance states, and cortical temperature. Am J Physiol 1991;261:R198-R208.
236. Dibner C, Schibler U, Albrecht U. The mammalian circadian timing system: organization and coordination of central and peripheral clocks. Annu Rev Physiol 2010;72:517-49.
237. Welsh DK, Takahashi JS, Kay SA. Suprachiasmatic nucleus: cell autonomy and network properties. Annu Rev Physiol 2010;72:551-77.
238. Ukai H, Ueda HR. Systems biology of mammalian circadian clocks. Annu Rev Physiol 2010;72:579-603.
239. Hattar S, Liao HW, Takao M, Berson DM, Yau KW. Melanopsin-containing retinal ganglion cells: architecture, projections, and intrinsic photo-sensitivity. Science 2002;295:1065-70. (Pubitemid 34132235)
240. Cheng MY, Bullock CM, Li C, et al. Prokineticin 2 transmits the behavioural circadian rhythm of the suprachiasmatic nucleus. Nature 2002;417:405-10. (Pubitemid 34563527)
241. Kramer A, Yang FC, Snodgrass P, et al. Regulation of daily locomotor activity and sleep by hypothalamic EGF receptor signaling. Science 2001;294:2511-5. (Pubitemid 34027284)
242. Chou TC, Scammell TE, Gooley JJ, Gaus SE, Saper CB, Lu J. Critical role of dorsomedial hypothalamic nucleus in a wide range of behavioral circadian rhythms. J Neurosci 2003;23:10691-702. (Pubitemid 37485283)
243. Buhr ED, Yoo SH, Takahashi JS. Temperature as a universal resetting cue for mammalian circadian oscillators. Science 2010;330:379-85.
244. Bass J, Takahashi JS. Circadian integration of metabolism and energetics. Science 2010;330:1349-54.